Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's Ocrevus: A Rare First-Year Blockbuster

Executive Summary

Ocrevus generated roughly $935m in 2017 after launching in April, exceeding recent drug launches and putting the multiple sclerosis therapy in company with early successes like Opdivo, Ibrance, Tecfidera and Eylea.

You may also be interested in...



TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS

The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.

Novartis' Kesimpta Goes Up Against Roche's Ocrevus In MS

The anti-CD20 monoclonal antibody was approved by the US FDA for relapsing multiple sclerosis, bringing a new treatment to the crowded therapeutic area – with the benefit of self-administration. 

Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline

Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel